Cancer therapy using a self-replicating RNA vaccine

Area of Science:

• Immunology
• Virology
• Oncology

Background:

• 'Naked' nucleic acid vaccines offer potential for cancer therapy but require improved efficacy.
• Enhancing immunogenicity is key to developing effective nucleic acid vaccines.

Purpose of the Study:

• To enhance the immunogenicity of nucleic acid vaccines by creating 'self-replicating' RNA immunogens.
• To evaluate the efficacy of self-replicating RNA (srRNA) vaccines in preclinical cancer models.

Main Methods:

• Constructed srRNA vectors using a Semliki forest virus-derived RNA replicase gene and a model antigen.
• Administered srRNA vaccines via intramuscular injection in mice.
• Assessed antigen-specific antibody and CD8+ T-cell responses.
• Evaluated protection against tumor challenge and survival in mice with established tumors.

Main Results:

• A single dose of 0.1 microg srRNA elicited antigen-specific antibody and CD8+ T-cell responses.
• srRNA vaccination protected mice from tumor challenge and prolonged survival.
• In vitro antigen production was comparable to DNA vaccines, but in vivo efficacy was enhanced.
• Enhanced efficacy correlated with caspase-dependent apoptosis and dendritic cell uptake.

Conclusions:

• Naked, non-infectious, self-replicating RNA represents a promising platform for novel cancer vaccine development.
• The mechanism of enhanced immunogenicity may involve apoptosis-induced uptake by dendritic cells.